← Back to headlines
Biogen and UCB's lupus drug dapirolizumab pegol meets Phase 3 primary endpoint
The experimental lupus drug dapirolizumab pegol, developed by Biogen and UCB, has successfully met its primary goal in a Phase 3 clinical trial, marking a significant step forward in treatment options for the autoimmune disease.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
